Navigation Links
RadMD reaches 150th clinical trial
Date:10/5/2009

DOYLESTOWN, Penn., Oct. 5, 2009 Completing a major milestone in its three years of operation, RadMD LLC (www.rad-md.net) announced that it has sourced readers for 150 clinical trials.

The most recent trial, conducted by ICON Medical Imaging for a leading pharmaceutical company, was designed to test the efficacy of a new treatment for metastatic kidney cancer. The trial used medical imaging to support the primary analysis of Progression Free Survival based on an independent central radiological review.

"The results of the reads showed that the drug delayed tumor growth by five months, with patients living twice as long without tumor growth as other cancer victims in the study's control arm. Ultimately, this provided the FDA with the information it needed to approve the drug," said Ted Gastineau, president and co-founder, ICON Medical Imaging. "Quality reads are critical and delays cost money and keep drugs from getting to the people who need it most. We are confident that RadMD's blinded readers have the skills and experience necessary to help us support our clients through the drug development process."

RadMD sourced five radiologists with a specialty in oncology within one week of the request and helped with resources and scheduling allowing completion of the analysis ahead of schedule. Each radiologist received formalized training and extensive testing on a variety of topics related to the use of medical imaging in clinical trials from the company's Blinded Reader and Investigator Training Institute (BRITI)TM. All CT scans, MRIs and bone scans obtained at baseline during the treatment period and the follow-up period were sent to the independent imaging core lab at ICON Medical Imaging.

Founded by medical imaging experts Kohkan Shamsi, MD, PhD, and Richard Patt, MD, RadMD sources clinical experts and provides consulting services for pharmaceutical, biotech and medical device trials an
'/>"/>

Contact: Pablo Andreu
pablo@feintuchpr.com
212-808-4903
Feintuch Communications
Source:Eurekalert

Page: 1 2

Related biology news :

1. Undergraduate bioscience research reaches new horizons
2. PNNL reaches goal to change world one light at a time
3. Montana State University research reaches Supreme Court of India
4. Saving Sumatra: Indonesia reaches historic agreement
5. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
6. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
7. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
8. Cleveland Clinic leading clinical program to improve early-stage lung cancer detection
9. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
10. Study of African traditional medicine will begin world-first clinical trial
11. New clinical data shows chromium picolinate improves cognitive function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
(Date:8/5/2015)... 5, 2015 The biosensors market is proving ... penetration into newer sectors, and development of devices resulting ... space has seen the entry of multiple participants each ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... of the Global Biosensors Market ( http://www.frost.com/nee9 ), ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... in The Netherlands have developed a technique for generating atom ... so-called super atoms (clusters of 13 silver atoms, for example) ... opened up a whole new branch of chemistry. A full ... Delft magazine Delft Outlook . If a ...
... 1, 2008) Recipe to recover more quickly from exercise: ... or six cups of strong coffee. Glycogen, the ... rapidly when athletes ingest both carbohydrate and caffeine following ... the Journal of Applied Physiology shows. Athletes ...
... CHICAGO The July 2008 issue of the Journal of ... may find of interest. Below is a summary of some of ... copy of a Journal article, e-mail media@eatright.org . ... ways to manage their weight are often advised to eat slowly, ...
Cached Biology News:Super atoms turn the periodic table upside down 2Post-exercise caffeine helps muscles refuel 2Post-exercise caffeine helps muscles refuel 3Post-exercise caffeine helps muscles refuel 4Highlights from the July 2008 Journal of the American Dietetic Association 2
(Date:8/28/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today ... 30, 2015, corporate highlights, and near-term milestones.  The ... at www.sedar.com ,  www.edgar.com and ... expects to launch its RCS-01 treatment for aging ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... opportunity for venture capital funds, investment firms and animal health companies to hear ... have raised $160 million. Several have also received licensing agreements or distribution contracts. ...
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its ... Biorem,s complete second quarter financial statements and MD&A have been filed ... earnings per shareThree-months ended , Six -months endedJune 30 , June ... , 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
... , , , ... Over the past decade, many organisms have been the,subject of large-scale genome projects, ... analysis. Knowledge of tissues and cells,that express particular genes is key to understanding,gene ... , , Microarrays and similar high-throughput gene ...
... , , , ... , , Choose Shrimp Alkaline Phosphatase,for ... , , , ... Phosphatase.,Avoid phenol:chloroform extractions; after dephosphorylation,inactivate Shrimp Alkaline Phosphatase completely,and irreversibly by heating at ...
... , , , , ... larger pack sizes,of PCR-Grade Nucleotides. These larger pack sizes,combine the best available quality with attractive pricing. ... , Single dNTPs , , ... are now available in 500-mol pack sizes.,The Deoxynucleoside Triphosphate Set, containing all four dNTPs (dATP, dCTP, ...
Cached Biology Technology:The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 2The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 3The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 4The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 5The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 6PCR-Grade Nucleotides,Larger Pack Sizes Now Available 2
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... ( Abpromise for all tested applications). ... KLH derived from within residues 500 to the ... acid sequence is proprietary) (Peptide ... Entrez Gene ID: 51043 ...
Rabbit polyclonal to SUR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide Entrez Gene ID: 6833 Swiss Protein ID: Q09428...
Biology Products: